Endpoint
Arginine-to-ornithine ratio
CAT:outcome/arginine-ornithine-ratioreported in ratio1 finding from 1 compound
What moved it
How to read these marks1 finding · 1 compound · 1 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| L-arginine | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Every finding here is a null result.
Measured, no effect detected
1 finding
L-arginine — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Pharmacodynamic analysis confirmed increased plasma arginine levels but showed no significant change in the arginine-to-ornithine ratio.”
Quoted verbatim from Arginine therapy in sickle cell disease: A systematic review and meta-analysis of clinical outcomes.. - Study
- meta-analysis
- Population
- Sickle cell disease patients with vaso-occlusive crises; meta-analysis of 8 RCTs (n=830) of L-arginine vs placebo or standard care; pharmacodynamic sub-analysis
Arginine therapy in sickle cell disease: A systematic review and meta-analysis of clinical outcomes.2026PMID:41534622Permalink
How it is measured
Ratio of plasma arginine concentration to plasma ornithine concentration measured on the same specimen, used to index arginase-mediated diversion of arginine.
Sources cited
1 paper
- Subject
- arginine-to-ornithine ratio
- Findings
- 1
- Papers
- 1